A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

被引：0
|
作者：
Antonarakis, E. S.
Heath, E. I.
Smith, D. C.
Rathkopf, D. E.
Blackford, A. L.
Danila, D. C.
King, S.
Frost, A.
Carducci, M. A.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    ONCOLOGIST, 2013, 18 (02): : 163 - 173
  • [2] A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    CANCER RESEARCH, 2012, 72
  • [3] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [4] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
    de Bono, J. S.
    Sandhu, S. K.
    Fizazi, K.
    Sun, J.
    Ward, A.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S998 - S998
  • [8] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [9] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium
    Harzstark, A. L.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Mi, J.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345